Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $62.22

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have been given an average rating of "Buy" by the nine research firms that are covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $59.25.

Several brokerages recently commented on JSPR. UBS Group reduced their price target on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Finally, Oppenheimer cut their target price on shares of Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of JSPR. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics during the 1st quarter worth $46,000. Corton Capital Inc. acquired a new position in shares of Jasper Therapeutics during the 1st quarter worth $113,000. Wells Fargo & Company MN increased its stake in shares of Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after purchasing an additional 3,828 shares during the last quarter. EntryPoint Capital LLC acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth $223,000. Finally, Tema Etfs LLC acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth $266,000. Institutional investors and hedge funds own 79.85% of the company's stock.

Jasper Therapeutics Stock Down 3.5%

NASDAQ:JSPR traded down $0.20 during trading hours on Wednesday, reaching $5.49. 1,982,104 shares of the company's stock were exchanged, compared to its average volume of 309,526. The company has a market capitalization of $82.46 million, a P/E ratio of -1.05 and a beta of 2.72. Jasper Therapeutics has a 12 month low of $3.13 and a 12 month high of $26.05. The business's 50-day simple moving average is $5.17 and its two-hundred day simple moving average is $7.37.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.24). As a group, sell-side analysts anticipate that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.